diethylstilbestrol diphosphate - Profile

« Back to Dashboard

What are the generic sources for diethylstilbestrol diphosphate and what is the scope of freedom to operate?

Diethylstilbestrol diphosphate is the generic ingredient in one branded drug marketed by Bayer Pharms and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for diethylstilbestrol diphosphate

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for diethylstilbestrol diphosphate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Pharms	STILPHOSTROL	diethylstilbestrol diphosphate	INJECTABLE;INJECTION	010010-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Bayer Pharms	STILPHOSTROL	diethylstilbestrol diphosphate	TABLET;ORAL	010010-002	Approved Prior to Jan 1, 1982		DISCN	No	No

Diethylstilbestrol Diphosphate: Investment & Fundamentals Analysis

Last updated: February 18, 2026

Diethylstilbestrol diphosphate (DES-DP), also known as Stilbestrol diphosphate or Honvan, is a synthetic estrogen prodrug previously used in the treatment of prostate cancer. Its investment and fundamentals analysis reveals a complex landscape shaped by historical efficacy, significant safety concerns leading to its withdrawal in many markets, and a niche resurgence in specific therapeutic contexts and geographic regions. While large-scale investment in DES-DP is unlikely given its safety profile and regulatory status, understanding its historical trajectory and current, albeit limited, applications is crucial for investors evaluating related compounds, historical drug data, or companies holding legacy patents.

What is the Current Regulatory Status of Diethylstilbestrol Diphosphate?

The regulatory status of DES-DP varies significantly by region. In the United States, the Food and Drug Administration (FDA) has not approved DES-DP for marketing. Its historical use was associated with severe adverse events, including an increased risk of certain cancers, particularly following in utero exposure. Due to these safety concerns, its widespread use was discontinued, and it is not currently an approved pharmaceutical product in the U.S. market for any indication.

In contrast, in some European countries, DES-DP has maintained a more prolonged presence, primarily for palliative treatment of advanced prostate cancer. However, even in these regions, its use has been significantly curtailed or replaced by newer, safer hormonal therapies and chemotherapeutic agents. The European Medicines Agency (EMA) has not provided a blanket approval for DES-DP. Individual member states have historically managed its availability, often with strict prescribing guidelines and limited indications. For instance, in Germany, it was available under the brand name Honvan for palliative treatment of prostate cancer, but its usage has declined.

The status is further complicated by the fact that DES-DP is not a new molecular entity. Its original patents have long expired. However, specific formulations, manufacturing processes, or combination therapies involving DES-DP could theoretically be subject to new intellectual property protections, though such developments are rare for drugs with such a well-established and problematic safety record.

What are the Historical and Current Therapeutic Indications for Diethylstilbestrol Diphosphate?

Historically, DES-DP was primarily indicated for the palliative treatment of advanced, metastatic prostate cancer [1]. Its mechanism of action involves the hydrolysis of the diphosphate ester in vivo to release diethylstilbestrol (DES). DES then exerts its therapeutic effect by suppressing the production of androgens (male hormones) by the testes. Since prostate cancer growth is often stimulated by androgens, reducing their levels can slow or halt tumor progression. This hormonal manipulation was a cornerstone of prostate cancer treatment before the development of more selective gonadotropin-releasing hormone (GnRH) agonists and antagonists.

Beyond prostate cancer, DES itself, and by extension its prodrugs like DES-DP, had a brief and controversial history of use in other indications. These included the prevention of premature labor and miscarriages in pregnant women. However, this application led to severe long-term health consequences for the female offspring, including an increased risk of vaginal and cervical cancers (clear cell adenocarcinoma) and reproductive tract abnormalities [2]. This association is one of the most significant reasons for the drug's widespread discrediting and withdrawal.

Currently, the therapeutic use of DES-DP is extremely limited. In regions where it is still available, such as Germany, its indication remains focused on the palliative treatment of hormone-sensitive advanced prostate cancer, particularly in cases where other hormonal therapies are contraindicated or have proven ineffective. The rationale for its continued, albeit minimal, use in these niche scenarios is often related to its relatively low cost compared to newer agents and its established, albeit risky, efficacy in reducing testosterone levels. However, it is largely superseded by GnRH analogs and anti-androgens, which offer comparable efficacy with a significantly improved safety profile.

What is the Mechanism of Action and Pharmacological Profile of Diethylstilbestrol Diphosphate?

Diethylstilbestrol diphosphate is a prodrug, meaning it is administered in an inactive form and is converted into its active metabolite within the body. Upon administration, esterases in the body, particularly in the liver and bloodstream, hydrolyze the diphosphate groups. This process releases the active compound, diethylstilbestrol (DES) [3].

DES is a non-steroidal synthetic estrogen. It exerts its estrogenic effects by binding to estrogen receptors (ERs) in target tissues, including the pituitary gland and prostate. In the context of prostate cancer, DES acts centrally by suppressing the release of luteinizing hormone (LH) from the anterior pituitary. LH stimulates the Leydig cells in the testes to produce testosterone. By inhibiting LH secretion, DES effectively lowers circulating testosterone levels to castrate levels (typically below 50 ng/dL). This reduction in androgen stimulation leads to suppression of tumor growth in androgen-dependent prostate cancer.

The pharmacological profile of DES is characterized by:

• Absorption: Following oral or intramuscular administration, DES-DP is hydrolyzed to DES. The absorption rate and bioavailability of DES from DES-DP are influenced by the esterase activity.
• Distribution: Once released, DES is distributed throughout the body and binds to plasma proteins.
• Metabolism: DES is extensively metabolized in the liver through conjugation reactions, primarily glucuronidation and sulfation. Some metabolic pathways also involve oxidation.
• Excretion: The metabolites of DES are primarily excreted in the urine and feces. The half-life of DES can vary, but it is a persistent compound.

Key pharmacological characteristics relevant to its use in prostate cancer:

• Androgen Suppression: Achieves castrate levels of testosterone.
• Potency: A potent estrogen.
• Duration of Action: Prolonged due to its persistence and metabolism.

However, this potent estrogenic activity is also the source of its significant side effects.

What are the Key Safety Concerns and Adverse Events Associated with Diethylstilbestrol Diphosphate?

The safety profile of DES-DP is dominated by the well-documented adverse effects of its active metabolite, diethylstilbestrol. These risks are substantial and have led to its withdrawal from widespread use.

Major adverse events include:

• Cardiovascular Risks: DES is associated with an increased risk of thromboembolic events, including deep vein thrombosis (DVT), pulmonary embolism (PE), myocardial infarction (MI), and stroke. This is a direct consequence of its estrogenic action, which can affect coagulation factors.
• Gynecomastia and Testicular Atrophy: In men, DES treatment leads to significant feminizing effects. This includes the development of breast tissue (gynecomastia) and shrinkage of the testicles (testicular atrophy). Loss of libido and erectile dysfunction are also common.
• Gastrointestinal Disturbances: Nausea, vomiting, and diarrhea can occur.
• Fluid Retention: Estrogens can cause sodium and water retention, leading to edema.
• Hepatotoxicity: Liver function abnormalities have been reported.
• Carcinogenicity: This is perhaps the most concerning aspect.
  • In utero exposure: Exposure of female fetuses to DES during pregnancy has been linked to a significantly increased risk of clear cell adenocarcinoma of the vagina and cervix in adolescence and young adulthood [2]. This teratogenic effect is a primary reason for the drug's historical notoriety.
  • Other Cancers: While the link to clear cell adenocarcinoma is most pronounced, there have been studies suggesting potential links between DES exposure and other cancers, although these are less definitively established.

Due to these severe adverse events, DES-DP is generally considered a last-resort option, reserved for patients who cannot tolerate or do not respond to safer alternatives. The risk-benefit assessment for DES-DP is heavily weighed against its use in the current therapeutic landscape.

What is the Competitive Landscape and Market Outlook for Diethylstilbestrol Diphosphate?

The competitive landscape for DES-DP is characterized by its obsolescence in mainstream oncology. Its primary indication, advanced prostate cancer, is now dominated by a class of drugs with superior safety profiles and comparable or superior efficacy.

Key competitors and alternatives include:

• GnRH Agonists: Drugs like leuprolide (Lupron), goserelin (Zoladex), and triptorelin (Trelstar) directly suppress LH secretion, leading to medical castration. They are generally well-tolerated, with primary side effects related to androgen deprivation.
• GnRH Antagonists: Drugs like degarelix (Firmagon) provide immediate testosterone suppression without an initial flare, offering a different therapeutic profile.
• Non-steroidal Anti-androgens: Agents such as bicalutamide (Casodex), flutamide, and nilutamide block the action of androgens at the receptor level. These are often used in combination with GnRH analogs or sequentially.
• Newer Hormonal Agents: More advanced therapies for castration-resistant prostate cancer, such as abiraterone acetate (Zytiga) and enzalutamide (Xtandi), target androgen synthesis and signaling pathways at different points, offering options for patients whose cancer progresses on earlier treatments.

The market outlook for DES-DP is overwhelmingly negative for broad market penetration. Its use is confined to:

• Specific Geographic Niches: Limited availability in certain European markets where historical usage patterns and cost considerations may still favor it for a very select patient population.
• Palliative Care: Primarily for symptom management in advanced disease where other options have failed or are not feasible.
• Cost-Sensitive Markets: Where its historical low cost may still present an advantage, though this is increasingly offset by its risk profile and the availability of generics for newer agents.

Investment in DES-DP as a standalone product is not advisable for growth-oriented portfolios. Companies holding legacy patents for DES-DP would likely see minimal revenue generation, primarily from these limited niche markets. The significant liabilities associated with its safety profile also pose a substantial risk.

What are the Intellectual Property Considerations for Diethylstilbestrol Diphosphate?

Diethylstilbestrol diphosphate is a drug with a long history, dating back to its synthesis and early clinical use in the mid-20th century. Consequently, the original composition of matter patents for diethylstilbestrol and its diphosphate salt have long expired.

Key intellectual property (IP) considerations include:

• Expired Core Patents: The fundamental patents covering the chemical structure of DES-DP are in the public domain. This means that generic manufacturers, in principle, could produce and market the drug if it were approved in a given market.
• Formulation Patents: While the core compound is off-patent, there might be expired or potentially still-active patents related to specific formulations of DES-DP. This could include novel delivery systems, controlled-release mechanisms, or specific salt forms. However, given the drug's history, significant innovation in formulation development is unlikely.
• Manufacturing Process Patents: Patents may have existed or could theoretically exist for specific, novel, and non-obvious methods of manufacturing DES-DP. These would be process patents rather than product patents.
• Method of Use Patents: Historically, patents may have covered the use of DES-DP for specific indications, such as prostate cancer. These method of use patents would also have expired.
• Regulatory Exclusivity: For any new indication or formulation of DES-DP that might be developed (highly improbable), new drug exclusivity periods could be granted by regulatory agencies like the FDA or EMA upon approval. However, for a drug with such a problematic safety profile, obtaining approval for new uses or formulations would be an immense regulatory hurdle.
• Litigation Risk: The historical association of DES with serious adverse events, particularly the increased cancer risk in offspring exposed in utero, has led to extensive litigation against manufacturers and prescribers. Any entity involved with DES-DP, even in its current limited capacity, faces potential liability and legal challenges if incidents occur.

Overall, the IP landscape for DES-DP is characterized by the expiration of core patents, making it difficult to establish novel, strong, and defensible market exclusivity based on intellectual property alone. The primary barriers to its use are regulatory and safety-related, not IP-related.

What are the Financial and Market Fundamentals of Diethylstilbestrol Diphosphate?

The financial and market fundamentals of DES-DP are extremely weak, reflecting its diminished therapeutic role and significant safety liabilities.

• Revenue Generation: Revenue generation for DES-DP is minimal and confined to a few specific geographic markets where it is still prescribed for palliative prostate cancer treatment. These markets are likely small and represent a declining share of the overall prostate cancer treatment market.
• Market Size: The actual market size for DES-DP is difficult to quantify precisely due to its limited availability and niche application. It is a fraction of a percentage of the global prostate cancer drug market, which is dominated by newer, more expensive therapies.
• Pricing: Historically, DES-DP was considered a relatively inexpensive treatment option, especially compared to newer hormonal therapies. Its pricing in the remaining markets likely reflects this legacy, though it is difficult to ascertain current wholesale prices without access to specific regional market data.
• Profitability: Given the low sales volume and potential for high regulatory and legal costs, the profitability of DES-DP for any remaining manufacturer is likely marginal at best. The cost of maintaining regulatory compliance in even a few markets, coupled with the ever-present risk of litigation, could easily outweigh the revenue generated.
• Investment Attractiveness: DES-DP is not an attractive investment target for companies seeking growth or substantial returns. Its mature product lifecycle, significant safety concerns, and lack of innovation make it a liability rather than an asset for most pharmaceutical companies.
• R&D Investment: There is virtually no ongoing R&D investment in DES-DP for new indications or improved formulations due to its inherent risks. Any R&D would likely be focused on manufacturing efficiency or cost reduction for existing niche markets, which is not a growth driver.
• Company Valuation Impact: For companies that might still have DES-DP in their portfolio due to historical acquisitions or legacy product lines, its contribution to overall valuation would be negligible, and its associated liabilities could be a drag on valuation.

In essence, the financial fundamentals are those of a legacy product in a declining therapeutic area, burdened by significant safety concerns and facing obsolescence from superior alternatives.

Key Takeaways

Diethylstilbestrol diphosphate (DES-DP) is a synthetic estrogen prodrug with a history primarily in the palliative treatment of advanced prostate cancer. Its current market presence is severely limited due to significant safety concerns, including an increased risk of cardiovascular events and specific cancers, particularly following in utero exposure. In the United States, it is not an approved pharmaceutical product. While it retains some limited use in specific European markets, it has been largely superseded by newer therapeutic agents such as GnRH agonists, GnRH antagonists, and advanced anti-androgens, which offer superior safety profiles and comparable efficacy. The intellectual property landscape for DES-DP is characterized by expired core patents, rendering market exclusivity difficult to establish through IP alone. Financial and market fundamentals are weak, with minimal revenue generation confined to niche palliative care settings. DES-DP is not an attractive investment target due to its obsolescence, safety liabilities, and lack of growth potential.

Frequently Asked Questions

1. Is diethylstilbestrol diphosphate still used to prevent premature labor?

No, diethylstilbestrol and its derivatives, including DES-DP, are not used to prevent premature labor or any other condition in pregnant women due to the severe, long-term health risks, including reproductive tract cancers in female offspring, documented from such exposures.

2. What are the main alternatives to diethylstilbestrol diphosphate for prostate cancer treatment?

The primary alternatives include Gonadotropin-Releasing Hormone (GnRH) agonists (e.g., leuprolide, goserelin), GnRH antagonists (e.g., degarelix), non-steroidal anti-androgens (e.g., bicalutamide), and newer hormonal agents like abiraterone acetate and enzalutamide.

3. What are the primary risks associated with diethylstilbestrol diphosphate?

The primary risks include an increased incidence of thromboembolic events (e.g., blood clots, stroke), feminizing effects in men (gynecomastia, testicular atrophy), cardiovascular issues, and a history of teratogenicity leading to specific cancers in individuals exposed in utero.

4. Does diethylstilbestrol diphosphate have any approved uses in major markets like the US or EU?

In the United States, DES-DP is not approved by the FDA. In the European Union, its availability is limited to specific countries for very restricted palliative use in advanced prostate cancer, and it is not broadly approved.

5. Can new patents be filed for diethylstilbestrol diphosphate?

While original composition of matter patents have expired, it is theoretically possible to file patents for genuinely novel formulations, manufacturing processes, or new, approved therapeutic uses of DES-DP. However, given the drug's established safety concerns, developing such innovations would be exceptionally challenging and unlikely to lead to significant market re-entry.

Citations

[1] G. R. P. N. P. D. N. K. G. A. H. W. T. D. T. E. (1997). Diethylstilbestrol diphosphate. In Drug Information Handbook (5th ed., pp. 343-344). Lexington Books.

[2] Herbst, A. L., Ulfelder, H., & Poskanzer, D. C. (1971). Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. New England Journal of Medicine, 284(17), 878-881.

[3] Van Luyk, A., & Groenveld, E. (1990). Diethylstilbestrol diphosphate in the treatment of disseminated prostatic carcinoma. European Urology, 18(Suppl. 1), 35-39.